# A Study of Avutometinib and Defactinib in People With Thyroid Cancer

> **NCT06007924** · PHASE2 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 30 (estimated)

## Conditions studied

- Thyroid Cancer

## Interventions

- **DRUG:** Avutometinib
- **DRUG:** Defactinib

## Key facts

- **NCT ID:** NCT06007924
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-16
- **Primary completion:** 2027-08-16
- **Final completion:** 2027-08-16
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-03-27

## Collaborators

- Verastem, Inc.

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06007924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06007924, "A Study of Avutometinib and Defactinib in People With Thyroid Cancer". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT06007924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*